What is FATE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.26B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for FATE?

P/E (TTM) is n/a and 52-week range is $0.95 to $3.23 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s FATE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for FATE?

The company profile lists revenue (TTM) near $6M, net income (TTM) near $-12.20B, EPS (TTM) near $-1.05 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Fate Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 116.6M shares outstanding, ISIN US31189P1021 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Fate Therapeutics Inc

$FATE

Health Care · Biotechnology

IR Run Scenarios

$2.18

+2.35%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 161 full-time employees. The company went IPO on 2013-10-01. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

Employees

161

Website

fatetherapeutics.com/

IPO

2013-10-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)